Real-life cohort participants with a discrepancy between SARS-CoV-2 RT-PCR and dog response
| Participants | Dog response | RT-PCR (viral load) | Symptoms | Time between symptom onset and skin swab/between RT-PCR test and skin swab, days | Antibody test result (time between RT-PCR test and antibody test, days) | Comment | SARS-CoV-2 infection status (variant*, if available) |
| RL1 | Negative | Positive (medium) | Asymptomatic | NA†/0 | Negative (81) | Two additional negative PCR tests | Negative (wild-type)‡ |
| RL2 | Negative | Positive (high) | Muscle aches, headache, fever | 1/0 | Positive (57) | Positive (alpha) | |
| RL3 | Negative | Positive (medium) | Asymptomatic | −10/0 | Positive (56) | Fever, cough, dyspnoea, headache 10 days before tests | Postinfectious prolonged PCR positivity (wild-type) |
| RL4 | Positive (two dogs) | Negative | Asymptomatic | NA/0 | Negative (178) | Negative scent dog test and PCR-test within 1 month | Negative |
| RL5 | Positive/Negative (two dogs) | Negative | Asymptomatic | NA/0 | Negative (97) | Negative | |
| RL6 | Positive (two dogs) | Negative | Chest pain, cough, tachycardia, fever | 1/0 | Negative (113) | Second PCR test negative 4 days after initial test | Negative |
| RL7 | Positive | Negative | Sore throat | −5/0 | Negative (55) | Negative |
*Variant, SARS-CoV-2 variant status was determined using S-Gene Target Failure, N501Y Mutation PCR and/or gene sequencing combined with epidemiological information (first alpha variant cases were detected 18 December in Finland).
†NA, not available.
‡Wild-type, refers to Wuhan like non_VoC lineages.
RT-PCR, reverse transcriptase-polymerase chain reaction.